CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
See how healthcare professionals selected individual treatment regimens for their patients using CUVITRU [Immune Globulin Subcutaneous (Human)] 20% Solution.
Results represent the experiences of 3 patients. Individual results may vary.
Hadlie Jo
“I like that it’s every other week instead of every week, so I can play or dance or whatever I want to do.”
– Hadlie Jo,
PI Patient, 9 years old Actual patient with PI
Results represent patient’s experiences. Individual results may vary. Patients should consult with their physician as needed.
Switched from a different
20% SCIG to CUVITRU
Hadlie Jo experienced recurrent respiratory tract infections from a young age.
†Cystic fibrosis test.
Initial visit with Dr.Wasserman at age 8
Laboratory findings
CBC=complete blood count.
*Ranges vary because testing was performed at 2 different laboratories
“One of the virtues of CUVITRU is that it helps decrease burden of care. That’s a relatively new concept in the area of immunodeficiency, but I think it’s important.”
-Dr. Richard Wasserman
Allergist/
Immunologist
Dr. Wasserman is a paid consultant of Takeda
Initial treatment at age 8
Initial SCIG treatment results
“I’m on 3 dance teams and I’m really active, and the treatments every week would slow me down. Now that I’m doing it every other week, I feel like I have more time to dance.”
-Hadlie Jo, PI Patient
CUVITRU treatment plan
CUVITRU treatment results*
URI=upper respiratory infection
*Results represent one patient's experience. Individual results may vary. Patients should consult their physician as needed. Click here for reported side effects with CUVITRU in clinical trials.
Julie
“CUVITRU has been very life-friendly, including the set-up frequency. After my infusion, I don’t have to think about it again for 2 more weeks.”
– Julie,
PI Patient, 55 years oldActual patient with PI
Results represent patient’s experiences. Individual results may vary. Patients should consult with their physician as needed.
Switched from a 10% IVIG
to CUVITRU
From her early childhood, Julie struggled with being sick and was constantly in the hospital for asthma and other health issues.
Initial evaluation and diagnoses at age 52
Relevant medical history
Laboratory findings
“With CUVITRU she’s able to do what she wants to do. The customizable aspect is really lovely.”
“It became difficult to access her veins over time. The long IV infusions and the systemic side effects were affecting her, and so the decision was made to transition to CUVITRU.”
-Dr. Ankmalika (Malika) Gupta
Allergist/
Immunologist
Dr. Gupta is a paid consultant of Takeda
Initial treatment results
CUVITRU treatment plan
CUVITRU treatment results*
*Results represent one patient’s experience. Individual results may vary. Patients should consult their physician as needed. Click here for reported side effects with CUVITRU in clinical trials.
“It was so much more convenient—from less infusion time to how I felt immediately after. And it took away that whole down week that I would lose with the IV infusion.”
-Julie, PI patient
Walter
“Now I’m back to living my life. My CUVITRU administration schedule helped give me that freedom.”
– Walter,
PI Patient, 59 years oldActual patient with PI
Results represent patient’s experiences. Individual results may vary. Patients should consult with their physician as needed.
Switched from a different
20% SCIG to CUVITRU
Walter experienced recurrent infections such as sinusitis from the age of 16.
Initial evaluation and diagnoses at age 54
2013-14
2014-15
Dramatic decline in health
“CUVITRU is a great option for Walter. With the reduced infusion time, he’s doing whatever he wants to do again when he wants to do it, and so that’s one of the things that is very exciting.”
-Dr. Diana Cavanah
Allergist/
Immunologist
Dr. Cavanah is a paid consultant of Takeda
Evaluation and diagnoses at age 57
2016
Presented with bronchiectasis/recurrent pneumonia
Initial SCIG treatment in July 2016
Initial SCIG treatment results
“I found as I was experiencing pneumonia more frequently that I was beginning to tailor my life’s activities to avoid potential situations where I might have a problem with getting the flu or pneumonia.”
-Walter, PI patient
CUVITRU treatment plan
CUVITRU treatment results*
Walter did not require antibiotics (no oral antibiotics or nebulized tobramycin) for lung infections in over a year
*Results represent one patient’s experience. Individual results may vary. Patients should consult their physician as needed. Click here for reported side effects with CUVITRU in clinical trials.